Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” at StockNews.com
StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a research note published on Sunday morning. Separately, HC Wainwright reaffirmed a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a research report on Friday, August 16th. View Our Latest […]
10 Oct 01:32 · The Cerbat Gem